Immune Suppression in Tumors as a Surmountable Obstacle to Clinical Efficacy of Cancer Vaccines
AbstractHuman tumors are usually not spontaneously eliminated by the immune system and therapeutic vaccination of cancer patients with defined antigens is followed by tumor regressions only in a small minority of the patients. The poor vaccination effectiveness could be explained by an immunosuppressive tumor microenvironment. Because T cells that infiltrate tumor metastases have an impaired ability to lyse target cells or to secrete cytokine, many researchers are trying to decipher the underlying immunosuppressive mechanisms. We will review these here, in particular those considered as potential therapeutic targets. A special attention will be given to galectins, a family of carbohydrate binding proteins. These lectins have often been implicated in inflammation and cancer and may be useful targets for the development of new anti-cancer therapies. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Wieërs, G.; Demotte, N.; Godelaine, D.; Van der Bruggen, P. Immune Suppression in Tumors as a Surmountable Obstacle to Clinical Efficacy of Cancer Vaccines. Cancers 2011, 3, 2904-2954.
Wieërs G, Demotte N, Godelaine D, Van der Bruggen P. Immune Suppression in Tumors as a Surmountable Obstacle to Clinical Efficacy of Cancer Vaccines. Cancers. 2011; 3(3):2904-2954.Chicago/Turabian Style
Wieërs, Grégoire; Demotte, Nathalie; Godelaine, Danièle; Van der Bruggen, Pierre. 2011. "Immune Suppression in Tumors as a Surmountable Obstacle to Clinical Efficacy of Cancer Vaccines." Cancers 3, no. 3: 2904-2954.